Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

162.81 -0.18 (-0.11%)
Official Closing Price Updated: 7:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,235,807
Open 162.12
Bid (Size) 162.22 (10)
Ask (Size) 162.80 (5)
Prev. Close 162.99
Today's Range 161.10 - 163.15
52wk Range 140.68 - 169.99
Shares Outstanding 2,628,679,824
Dividend Yield 3.05%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kroger CEO Shake-Up
Via The Motley Fool
Cool, Calm, and Collected: 2 Dividend ETFs to Buy During the S&P 500 Sell-Off
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities

Performance

YTD
+13.05%
+13.05%
1 Month
+4.86%
+4.86%
3 Month
+11.04%
+11.04%
6 Month
-1.64%
-1.64%
1 Year
+2.26%
+2.26%

More News

Read More
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
What 14 Analyst Ratings Have To Say About Johnson & Johnson
Via Benzinga
What the Options Market Tells Us About Johnson & Johnson
Via Benzinga
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?
Via The Motley Fool
Topics ETFs
Are High-Yield Dividend Stocks Best For Income-Focused Investors?
Via Talk Markets
Topics Stocks / Equities
How Exxon Mobil, Johnson & Johnson, And Cogent Communications Can Put Cash In Your Pocket
Via Benzinga
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger
Via The Motley Fool
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Via Benzinga
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Via Investor's Business Daily
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
3 Dividend Kings Shaking Off Market Woes
Via Talk Markets
Topics Stocks / Equities World Trade
Exposures Tariff
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Via Benzinga
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
Via Benzinga
Broaden Your ETF Exposure With These 3 Overlooked Funds
Via MarketBeat
Topics ETFs Economy Government
Exposures Economy Interest Rates Political
2 Dow Stocks to Buy Hand Over Fist in March and 1 to Avoid
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
From Johnson & Johnson
Via Business Wire
Tech Sector Hammered As Trump's Tariff Plans Spark Market Selloff: Nvidia, ARM, Super Micro Lead Tech Bloodbath
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Warren Buffett's State of the Market
Via The Motley Fool
These Vanguard ETFs Show Where the Smart Money Is Moving Now
Via The Motley Fool
Topics ETFs
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.